Medicinal products with a maximum price of up to five euros may have an increase of 2.3% in 2027, according to a ordinance published today, which is exempt from the annual price review of certain medicines, including generic and biosimilar.
© Shutterstock
18/11/2026
by
Lusa
Os medicines sold in pharmacies with a maximum price of up to five euros can have an increase of 2.3% in 2027, according to a decree published today, which exempts from annual price review certain medicines, including generic and biosimilar.
For 2027, Portugal starts to consider Spain, France, Italy and Belgium as reference countries for the training and annual review of the maximum prices of medicines, according to the ordinance published in Diário da República and which enters into force on Thursday.
The comparison with the prices charged in these countries applies to medicines covered by the maximum price system, whether for pharmacies or for hospital use in the National Health Service.
According to the ordinance, the 2.3% update applies to medicines intended for dispensation in workshop pharmacy with a price of sale to the public (PVP) maximum of less than or equal to five euros.
The increase shall be calculated on the basis of the maximum price in force at the date of publication of the ordinance and shall depend on the initiative of the marketing authorisation holders, who must submit the new prices by 15 December 2026, which shall apply from 1 January 2027.
It also provides that non-generic and non-biological similar medicines dispensed in pharmacies, with a maximum PVP of 20 euros or less, are exempted from the annual price review.
In the case of non-generic and non-biological medicines similar to hospital use and dispensing at the National Health Service (SNS), the exemption applies to drugs with a maximum price of up to EUR 75.
In both cases, if the annual review results in a price below the respective limits, the value may be adjusted to EUR 20 or 75, depending on the type of medicinal product.
According to the order signed by the Secretary of State for Health, Ana Povo, the medicines included in the “list of essential medicines of a critical nature” are exempt from the application of the annual price review scheme, whether they are intended for dispensation in a workshop pharmacy or for the use and hospital discharge in the SNS.
Also generic and similar biological medicinal products are exempted from this scheme.
However, this exemption is without prejudice to the adjustment of the maximum prices of these medicinal products whose maximum price is higher than the maximum price of their reference medicinal product resulting from the annual price review.
In such cases, the maximum prices of generics and biosimilars shall not exceed the maximum price of their reference medicinal product resulting from the annual price review.
The holder of marketing authorisations for non-generic and non-organic medicinal products shall submit the prices resulting from the annual review by 15 December 2026 to enter into force on 1 January 2027.
In the case of generics and biosimilars that need adjustment, the submission deadline expires on January 15, 2027, with the new prices in force from February 1.




